C07K 2317/54
F2
Official title: F(ab')2
C07K2317/54 (F2) appears on 1,185 US grants and 1,855 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,185
- Published applications
- 1,855
- Assignees
- 665
- Inventors
- 2,922
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 6 | 0 |
| 1999 | 12 | 0 |
| 2000 | 20 | 0 |
| 2001 | 16 | 2 |
| 2002 | 9 | 18 |
| 2003 | 7 | 25 |
| 2004 | 11 | 35 |
| 2005 | 12 | 31 |
| 2006 | 16 | 30 |
| 2007 | 6 | 40 |
| 2008 | 16 | 20 |
| 2009 | 15 | 43 |
| 2010 | 21 | 33 |
| 2011 | 29 | 63 |
| 2012 | 37 | 56 |
| 2013 | 38 | 68 |
| 2014 | 46 | 101 |
| 2015 | 85 | 134 |
| 2016 | 78 | 190 |
| 2017 | 95 | 136 |
| 2018 | 95 | 134 |
| 2019 | 62 | 96 |
| 2020 | 87 | 142 |
| 2021 | 75 | 124 |
| 2022 | 59 | 87 |
| 2023 | 61 | 73 |
| 2024 | 67 | 79 |
| 2025 | 62 | 59 |
| 2026 | 29 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Vector for co-expressing genes of interest6 Oct 2026US 12,753,414 B2Gat Biosciences, S.L.
- Antibodies binding 4-1BB and uses thereof1 Sep 2026US 12,723,086 B2Nanjing Leads Biolabs Co., Ltd.
- Anti-claudin 18.2 antibody and use thereof1 Sep 2026US 12,723,098 B2Crage Medical Co., Limited
- Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for use in intervention and therapy of congestion in a patient in need thereof25 Aug 2026US 12,715,911 B2Adrenomed AG
- Tau binding compounds18 Aug 2026US 12,709,641 B2Voyager Therapeutics, Inc.
- Therapeutic compounds and methods17 Sep 2026US 2026/0274914 A1Regents of the University of Minnesota
- Stable and soluble antibodies inhibiting vegf17 Sep 2026US 2026/0274935 A1Novartis AG
- Engineered immune cells expressing anti-u5 snrnp200 antibodies and uses thereof10 Sep 2026US 2026/0263518 A1
- Compositions and methods for treating obesity and reducing fat accumulation10 Sep 2026US 2026/0265369 A1
- Bispecific t cell activating antigen binding molecules10 Sep 2026US 2026/0265377 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Immunoglobulin variants1,380US 5,821,337 AGenentech, Inc. · 1998
- Humanized antibodies and methods for making them1,003US 6,054,297 AGenentech, Inc. · 2000
- Method for making humanized antibodies943US 6,407,213 B1Genentech, Inc. · 2002
- Antibody formulation655US 6,171,586 B2Genentech, Inc. · 2001
- Low pH hydrophobic interaction chromatography for antibody purification599US 5,641,870 AGenentech, Inc. · 1997